Shanghai, China — September 6, 2026
Fosun Pharma announced an H-share repurchase plan of up to HK$1 billion, marking a significant move in the company’s ongoing capital management and shareholder-return strategy. The company said the repurchase plan has already taken effect and will be implemented as soon as practicable, with shares acquired under the program potentially cancelled or held as treasury shares. Fosun Pharma said the initiative reflects management’s confidence in the company’s intrinsic value and is intended to respond directly to market concerns while strengthening its long-term value management framework. Rather than treating the repurchase as a one-time capital action, the company plans to evaluate market conditions dynamically and execute purchases on a rolling basis. This approach establishes a more normalized mechanism for shareholder returns while giving Fosun Pharma flexibility to manage its capital structure in response to market conditions. The announcement positions the repurchase as an important component of the company’s broader financial strategy.
Gland Pharma Proceeds to Fund Strategic Capital Allocation
A key element of Fosun Pharma’s repurchase strategy is the planned use of proceeds from the disposal of approximately 6.00% of its equity interest in Gland Pharma, a transaction carrying total consideration of approximately US$294 million. Following completion, Fosun Pharma is expected to retain approximately 45.76% ownership of Gland Pharma, allowing the company to remain the promoter and continue consolidating Gland Pharma within its financial statements. The transaction therefore provides Fosun Pharma with additional capital flexibility without eliminating its strategic exposure to its overseas pharmaceutical business. According to the company, the net proceeds will primarily support three areas: R&D investment, H-share repurchases and repayment of interest-bearing debt. This allocation highlights Fosun Pharma’s effort to balance investment in future growth with financial discipline and direct shareholder returns. The Gland Pharma transaction is particularly important to the wire story because it demonstrates how Fosun Pharma is recycling capital from an existing overseas asset into a combination of innovation funding, balance-sheet management and shareholder-value initiatives.
Fosun Pharma Reports Stronger First-Half Financial Performance
The repurchase announcement follows improvements in Fosun Pharma’s core operating indicators during the first half of 2026. The company reported revenue of RMB20.442 billion, representing a 4.75% year-over-year increase. Profit attributable to shareholders of the listed company, excluding non-recurring gains and losses, reached RMB1.144 billion, increasing 19.09% year over year. Net cash generated from operating activities was RMB2.424 billion, up 13.59% year over year. These figures provide the financial backdrop for the company’s decision to strengthen capital returns while continuing to invest in its business. Fosun Pharma said the quality of earnings continued to improve, supported by growing contributions from innovative medicines and international markets. From a corporate-wire perspective, the combination of improved profitability, stronger operating cash generation and proceeds from the Gland Pharma transaction gives the company greater flexibility in determining how capital is deployed. The repurchase therefore forms part of a wider capital-allocation strategy rather than an isolated financial action.
Advertisement
Innovation and Globalization Remain Core Strategic Priorities
Looking ahead, Fosun Pharma said it will continue focusing on innovation and globalization, while accelerating development and commercialization across its major pipeline programs. The company maintains strategic priorities across areas including oncology, immunology and inflammation, neurodegenerative diseases, cardiometabolic diseases and rare diseases, supported by technology platforms spanning antibodies, antibody-drug conjugates, small molecules and cell therapy. Fosun Pharma is also advancing newer modalities including radiopharmaceuticals and small nucleic acids, but the company’s latest announcement places particular emphasis on converting financial resources into sustainable long-term value. Its innovative products are marketed across more than 90 countries and regions, supporting the company’s international growth strategy. With the new HK$1 billion H-share repurchase program, continued investment in R&D and planned debt repayment, Fosun Pharma is pursuing a capital strategy designed to balance shareholder returns with future business expansion. The company’s continued ownership of Gland Pharma also preserves an important overseas platform while allowing capital to be redeployed toward strategic priorities.
Source: Fosun Pharma press relese
